Cargando…

Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept

BACKGROUND: Patients with polyarticular-course juvenile idiopathic arthritis (pJIA), receiving disease-modifying anti-rheumatic drugs with immunosuppressive effects, may be at increased risk of vaccine-preventable infections. This substudy assessed protective antibody responses to diphtheria and tet...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brunner, Hermine I., Tzaribachev, Nikolay, Cornejo, Gabriel Vega, Joos, Rik, Gervais, Elisabeth, Cimaz, Rolando, Calvo Penadés, Inmaculada, Cuttica, Rubén, Lutz, Thomas, Quartier, Pierre, Gandhi, Yash, Nys, Marleen, Wong, Robert, Martini, Alberto, Lovell, Daniel J., Ruperto, Nicolino
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Short Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7036185/ https://www.ncbi.nlm.nih.gov/pubmed/32087715 http://dx.doi.org/10.1186/s12969-020-0410-x

Ejemplares similares

Subcutaneous Abatacept in Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: Results From a Phase III Open‐Label Study
por: Brunner, Hermine I., et al.
Publicado: (2018)

Efficacy and Safety of Tocilizumab for Polyarticular‐Course Juvenile Idiopathic Arthritis in the Open‐Label Two‐Year Extension of a Phase III Trial
por: Brunner, Hermine I., et al.
Publicado: (2021)

Model‐Based Selection and Recommendation for Subcutaneous Abatacept Dose in Patients With Polyarticular Juvenile Idiopathic Arthritis
por: Gandhi, Yash, et al.
Publicado: (2021)

Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Abatacept in the treatment of polyarticular JIA: development, clinical utility, and place in therapy
por: Goldzweig, Ofra, et al.
Publicado: (2011)

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study
por: Ruperto, Nicolino, et al.
Publicado: (2017)

7.4 Improvements in individual disease components are sustained with long-term adalimumab therapy for polyarticular Juvenile Idiopathic Arthritis
por: Ruperto, N, et al.
Publicado: (2008)

Indirect comparison of etanercept and abatacept efficacy and safety in patients with polyarticular juvenile idiopathic arthritis
por: Loskutova (Konopelko), OU, et al.
Publicado: (2014)

Tetanus in Diphtheria Antitoxin
Publicado: (1901)

Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial
por: Brunner, Hermine I, et al.
Publicado: (2015)

Treating to target of minimal disease activity and normal function in polyarticular juvenile idiopathic arthritis with adalimumab: analysis from a phase 3 clinical trial
por: Ruperto, Nicola, et al.
Publicado: (2014)

Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritis
por: Ruperto, Nicolino, et al.
Publicado: (2021)

Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trial
por: Brunner, Hermine I, et al.
Publicado: (2018)

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
por: Brunner, Hermine I., et al.
Publicado: (2020)

PReS-FINAL-2180: Efficacy and safety of tocilizumab (TCZ) in patients with polyarticular-course juvenile idiopathic arthritis (pcJIA): 2-year data from CHERISH
por: De Benedetti, F, et al.
Publicado: (2013)

Long-term outcomes in patients with polyarticular juvenile idiopathic arthritis receiving adalimumab with or without methotrexate
por: Lovell, Daniel J, et al.
Publicado: (2020)

Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension
por: Ruperto, Nicolino, et al.
Publicado: (2009)

Abatacept treatment improves health-related quality of life, pain, and sleep quality in juvenile idiopathic arthritis patients
por: Ruperto, N, et al.
Publicado: (2008)

Immunogenicity and Safety of Diphtheria-tetanus Vaccine in Adults
por: Choi, Jung-Hyun, et al.
Publicado: (2010)

Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study
por: Schiff, Michael, et al.
Publicado: (2011)

Intravenous abatacept in Japanese patients with polyarticular-course juvenile idiopathic arthritis: results from a phase III open-label study
por: Hara, Ryoki, et al.
Publicado: (2019)

Estimating the Effectiveness of Tetanus-Diphtheria-Acellular Pertussis Vaccine
por: Decker, Michael D., et al.
Publicado: (2015)

Decennial diphtheria-tetanus adult boosters: are they really necessary?
por: TRUCCHI, C., et al.
Publicado: (2015)

Tetanus–diphtheria–acellular pertussis vaccination for adults: an update
por: Lee, Hyo-Jin, et al.
Publicado: (2017)

Booster vaccination against tetanus and diphtheria: insufficient protection against diphtheria in young and elderly adults
por: Grasse, Marco, et al.
Publicado: (2016)

PReS-FINAL-2327: Abatacept in the treatment of refractory uveitis
por: Moretti, D, et al.
Publicado: (2013)

Tocilizumab may slow radiographic progression in patients with systemic or polyarticular-course juvenile idiopathic arthritis: post hoc radiographic analysis from two randomized controlled trials
por: Malattia, Clara, et al.
Publicado: (2020)

2.3 Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular course juvenile rheumatoid arthritis (JRA): Findings from an open-label treatment extension
por: Ruperto, N, et al.
Publicado: (2008)

Analysis of the Immunogenicity from Abatacept‐Treated Pediatric Patients With Polyarticular‐Course Juvenile Idiopathic Arthritis: Findings From Two Phase III Clinical Trials
por: Mora, Johanna R., et al.
Publicado: (2021)

Cost of Delivering Tetanus Toxoid and Tetanus-Diphtheria Vaccination in Vietnam and the Budget Impact of Proposed Changes to the Schedule
por: Mai, Vu Quynh, et al.
Publicado: (2022)

The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR)
por: Dehoorne, Joke, et al.
Publicado: (2018)

Diphtheria, Tetanus, and Pertussis Immunity in Indian Adults and Immunogenicity of Td Vaccine
por: Kulkarni, Prasad S., et al.
Publicado: (2011)

Recall Responses to Tetanus and Diphtheria Vaccination Are Frequently Insufficient in Elderly Persons
por: Weinberger, Birgit, et al.
Publicado: (2013)

Seroprevalence of Antibodies against Diphtheria, Tetanus and Pertussis in Adult At-Risk Patients
por: Boey, Lise, et al.
Publicado: (2021)

Hypotonic-hyporesponsive Episodes After Diphtheria, Tetanus and Acellular Pertussis Vaccination
por: Hansen, John, et al.
Publicado: (2021)

Impact of childhood and maternal vaccination against diphtheria, tetanus, and pertussis in Colombia
por: Hoyos, Maria Cristina, et al.
Publicado: (2021)

Traumatic or Idiopathic Tetanus
por: Lovell, R.
Publicado: (1883)

Clinician awareness of tetanus-diphtheria vaccination in trauma patients: a questionnaire study
por: Yoon, Young-Hoon, et al.
Publicado: (2012)

Immunity to diphtheria and tetanus among blood donors in Arak, central province of Iran
por: Eslamifar, Ali, et al.
Publicado: (2014)

Clinical study of transcutaneous vaccination using a hydrogel patch for tetanus and diphtheria
por: Hirobe, Sachiko, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_qv486ku630v1l25pjd08mtpqma